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Background: myoclonus-dystonia (M-D) due to a pathogenic variant of SGCE is an 
autosomal dominant inherited movement disorder. Apart from motor symptoms, psychiatric 
disorders are highly prevalent in patients with M-D. Previous studies suggest, but never tested 
directly, that the type of psychiatric disorder differs between dystonia syndromes, probably 
related to disease specific pathology. Little is known about other non-motor symptoms (NMS) 
in M-D. Here, we systematically study NMS in M-D in direct comparison to other types of 
dystonia and healthy controls. 
Methods: standardized questionnaires were used to assess type and severity of psychiatric co-
morbidity, sleep problems, fatigue and quality of life. Results of M-D patients with a 
pathogenic variant of SGCE were compared to results of idiopathic cervical dystonia (CD) 
patients, dopa-responsive dystonia (DRD) patients with a pathogenic variant of GCH1 and  
controls.  
Results: we included 164 participants: 41 M-D, 51 CD, 19 DRD patients, 53 controls. 
Dystonia patients (M-D, CD and DRD) had an increased prevalence of psychiatric disorders 
compared to controls (56-74% vs. 29%). In M-D we found a significantly increased 
prevalence of obsessive-compulsive disorder (OCD) and psychosis compared to CD and 
DRD. All dystonia patients had more sleep problems (49-68% vs. 36%) and fatigue (42-73% 
vs. 15%) than controls. Compared to other dystonia subtypes, M-D patients reported less 
excessive daytime sleepiness and fatigue.  
Conclusion: psychiatric comorbidity is frequent in all dystonia types, but OCD and psychosis 






Myoclonus-dystonia (M-D) is a rare hyperkinetic movement disorder. About 50% of the 
patients have a known pathogenic variant in the epsilon-sarcoglycan gene (SGCE), which has 
an autosomal dominant inheritance pattern with maternal imprinting.[1] Symptoms usually 
start in the first or second decade of life. The typical clinical picture is that of a relatively mild 
dystonia in the hands (writer’s cramp) and neck, and more pronounced myoclonus in the 
upper body which is alcohol responsive.[2]  
Apart from the motor symptoms, non-motor symptoms (NMS), especially psychiatric 
disorders, are highly prevalent in patients with M-D. A large international study and other 
smaller studies showed a higher incidence of social phobias, alcohol dependence and 
obsessive compulsive disorder (OCD) in M-D patients.[3–5]  
In other types of dystonia, both focal and generalized forms,  psychiatric features are also 
common. Previous studies suggest that the type of psychiatric disorder differs between 
dystonia subtypes: depression is the main psychiatric disorder in early-onset generalized 
torsion dystonia, X-linked dystonia parkinsonism and dopa-responsive dystonia (DRD); 
anxiety disorders in focal dystonias; substance abuse and psychotic disorders in rapid-onset 
dystonia-parkinsonism.[6,7] However, each of these studies focused on one specific type of 
dystonia, and results are difficult to compare due to differences in methodology.  
In addition to the psychiatric disorders, other NMS that are prevalent in dystonia are sensory 
abnormalities, pain, sleep disorders, a high level of fatigue and cognitive problems. In 
general, patients with dystonia have a higher frequency of all these NMS, but there are no 
studies focusing on non-psychiatric NMS in M-D patients. It is important to note that NMS 
have a considerable influence on the quality of life (QoL) of dystonia patients.[8] Some 
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studies show that NMS have a larger impact on the QoL than the motor symptoms, 
highlighting the burden of NMS. 
Nowadays, the NMS are considered to be part of dystonia phenotypes rather than secondary 
to the social effect of living with a chronic movement disorder. The high prevalence of NMS 
in dystonia patients before the onset of motor symptoms supports this hypothesis.[7] 
Furthermore, lack of association between the severity of the psychiatric symptoms and the 
severity of motor symptoms in both cervical dystonia and generalized dystonia decreases the 
likelihood that NMS are a secondary effect of the motor symptoms.[9,10] If NMS are part of 
the phenotype and therefore share a pathophysiological pathway with the motor symptoms, 
we hypothesize that specific types of dystonia are associated with specific NMS.  
In this report, we performed a systematic assessment of psychiatric features, sleep disorders 
and fatigue in M-D and compared these to a group of normal controls without dystonia and 
two other types of dystonia that  are of special interest: idiopathic cervical dystonia (CD) and 
DRD. Dystonia of the neck is one of the predominant features of M-D. Although the age of 
onset in CD is later, the social impact and visibility for the environment are similar. DRD is a 
group of inherited disorders due to a defect in the synthesis of dopamine. In this study we 
chose to include only the most common DRD type which is caused by an autosomal dominant 
inherited pathogenic variant in the GCH1 gene. Although not entirely correct, this form of 
DRD will be referred to as DRD in the rest of this article. It is suggested that NMS are part of 
the phenotype in DRD. The similar age of onset and comparable severity of symptoms, which 
usually do not lead to loss of independence, make DRD patients a suitable control group.  
Establishing which NMS are most prevalent in different dystonia syndromes may shed light 
on the pathophysiology of the NMS. Furthermore, more insight in NMS in different types of 








M-D patients with a confirmed pathogenic variant in the SGCE gene were included. Data of 
three control groups were used: 1) clinically confirmed isolated CD patients, 2) DRD patients 
with a confirmed pathogenic variant in the GCH1 gene, 3) controls without a movement 
disorder (results were previously reported [8,9,11]). All participants were adults (age ≥ 18 
years). Exclusion criteria were the presence of other neurological conditions or treatment with 
deep brain stimulation. In addition, healthy participants with relatives with dystonia and, due 
to exclusion criteria of the previous study[8,11], CD patients using antidepressant treatment 
were excluded.  Patients were recruited in several Dutch hospitals and via the dystonia patient 
association,  some M-D patients were also recruited from Belgium. Controls were 
acquaintances of patients or investigators or were recruited by advertisements. Informed 
consent was obtained from all participants and the study was approved by the medical ethics 
committee of the University Medical Center Groningen (METc 2014/034). 
Clinical characteristics, NMS and QoL 
Clinical and demographic characteristics of the patients were obtained by a standardized 
interview. Information about the duration of dystonia and medication regimen were recorded. 
A standardized videotaped examination was performed in all patients. The severity of the 
motor symptoms was scored by two independent experts. The 7-point Clinical Global 
Impression Scale (CGI-S) was used to score motor severity in all patients.[12] In M-D, 
severity of dystonia was assessed with the Burke Fahn Marsden Dystonia Rating Scale 
(BFMDRS)[13], and severity of myoclonus with an abbreviated version of the Unified 
Myoclonus Rating Scale (UMRS).[14] In the CD group the severity of the torticollis was 
assessed with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).[15] In the 
DRD group the BFMDRS was used to assess severity of dystonia. The presence of psychiatric 
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disorders, including substance and alcohol abuse, as defined in the Diagnostic and Statistical 
Manual of Mental Disorders Fourth Edition (DSM-IV), was evaluated with the Mini 
International Neuropsychiatric Interview – PLUS (MINI-PLUS).[16] The severity of current 
depressive, anxious and obsessive compulsive symptoms were assessed with  respectively the 
Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI) and the Yale Brown 
Obsessive Compulsive Scale (YBOCS).[17–19] Impaired sleep quality was assessed with the 
Pittsburgh Sleep Quality Index (PSQI), excessive daytime sleepiness with the Epworth 
Sleepiness Scale (ESS) and fatigue was assessed with the Fatigue Severity Scale (FSS).[20–
22] The RAND-36 item Health Survey (RAND-36) was used to assess the QoL.[23] More 
information and cut-off values of the questionnaires can be found in supplementary table 1.  
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics version 23. A p-value <0.05 
was considered statistically significant. All baseline data were quantitatively described. A 
pairwise deletion of missing data was used. 
Fisher-Freeman-Halton exact tests were performed to compare the presence of a DSM-IV 
diagnosis between respectively all groups and the three patient groups. For variables which 
showed a significant difference between the patient groups post hoc analysis were performed 
using a Bonferroni corrected p-value.  
One way ANOVA, or in case of non-normality Kruskal Wallis test, was performed to 
compare the psychiatric, sleep and QoL scales between all groups and the three patient 
groups. Post-hoc analysis with Bonferroni correction of the p-values was performed for the 
variables which showed a significant difference. The scores on the domains of the RAND36 
were combined into a mental health component and a physical health component using factor 
analysis as described previously.  
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We performed a correlation analysis to assess the association of age of onset with the 
presence of psychiatric co-morbidity. Next, logistic regression was performed on the variables 
with a p-value of <0.05 in the correlation analysis. Odds ratios with and without age at onset 
as covariate were compared. To assess the influence of motor symptoms on having a  
psychiatric disorder a binary logistic regression analysis was performed.  
Associations between QoL and clinical characteristics were assessed using correlation 
analysis. With multivariate regression analysis, we determined the influence of the variables 
with a p <0.05 in the univariate correlation analysis. Assumptions of normality, 





We included 164 participants: 41 M-D patients, 51 CD patients, 19 DRD patients, and 53 
controls. The mean age was 49 years (range 22-75 years) in M-D patients, 54 years (range 20-
80) in CD patients, 51 years (range 22-77) in DRD patients, and 53 years (range 20-83) in 
controls.  No significant differences in age and gender were found between groups. Age of 
onset was significantly higher in CD patients (43 years, range 18-70) than in M-D patients (6 
years, range 0-50) and DRD patients (7 years, range 1-20). Clinical characteristics are 
described in table 1.  
Nine patients with M-D were treated with medication, most often with clonazepam (n=6), but 
also treatment with levetiracetam (n=2), trihexyphenidyl or valproate acid (both n=1) was 
reported. Almost all CD patients (n=47) received botulinum toxin injections and most DRD 
patients (n=17) were on levodopa treatment. Six M-D patients received antidepressant 
treatment with paroxetine (n=3), venlafaxine (n=2) or escitalopram (n=1). None of the CD 
patients and controls received treatment with antidepressants. Three DRD patients were on 
treatment with either mirtazapine (n=2) or paroxetine (n=1).  
Psychiatry 
Dystonia patients had visited their family doctor or mental health care professional due to 
mental problems significantly more often compared to controls (dystonia patients 65% (M-
D=68%, CD=65%, DRD=58%) vs. controls 35%; p=0.01). Accordingly, 56% of the M-D 
patients met the criteria of any psychiatric disorder according to the DSM-IV at any point in 
their lives, which was comparable to the prevalence in CD (65%) and DRD (74%) patients 




The prevalence of almost all studied DSM-IV diagnoses were significantly different between 
the four groups (table 2). When the results of M-D patients were compared to the other two 
dystonia groups, a significant difference was found in the presence of obsessive compulsive 
disorder (OCD) (M-D=20%, CD=2% and DRD=11%, p=0.01), generalized anxiety (M-
D=5%, CD=12% and DRD=47%, p=0.00), and psychosis (M-D=10%, CD=0% and 
DRD=0%, p=0.03). Post hoc analysis showed significantly more OCD in M-D patients 
compared to CD patients (p=0.03). Moreover, there was a higher prevalence of generalized 
anxiety in the DRD group compared to the M-D (p=0.00) and CD patients (p=0.01). 
To rule out any biases due to age at onset, we performed a correlation analysis to assess the 
association of this variable with the presence of psychiatric co-morbidity (supplementary table 
2). Next, logistic regression was performed on the variables with a p-value of <0.05 in the 
correlation analysis. Odds ratios with and without age at onset as covariate were compared. 
Results show that the age of onset of motor symptoms had an influence on the odds ratio of 
panic disorder and OCD between CD and DRD, and CD and M-D patients, meaning that age 
of onset might have some influence on our significant finding of more OCD in the M-D group 
(odds ratio: 0.083, p=0.02 vs. odds ratio with age of onset as covariate: 0.218, p=0.40)  
(supplementary table 3). We assessed whether motor symptom characteristics (severity, 
duration of dystonia, age of diagnosis, or duration of levodopa treatment) predict the presence 
of a psychiatric disorder. We  found no significant association between motor characteristics 
and  presence of a psychiatric disorder (supplementary table 4). 
Scores reflecting the severity of depression and anxiety were statistically different between 
the four groups (both p<0.01), but were not significantly different between the patient groups 




Sleep and fatigue 
In M-D, almost half of the patients subjectively reported to have sleep problems (49%) and in 
CD and DRD sleep problems were even more common (resp. 61% and 68%). This was 
significantly different compared to controls (36%, p=0.04). A large proportion (42%) of the 
M-D patients, 73% of the CD and 58% of the DRD patients reported that they were more 
easily fatigued than their peers. This is a significantly higher percentage than in the controls 
(15%, p=0.00).  
The scores on all questionnaires about sleep disturbances and fatigue were higher in the 
dystonia group compared controls (table 3). Moreover, the scores reflecting excessive daytime 
sleepiness (ESS) and quality of sleep (PSQI) differed significantly between patient groups. 
Post hoc analysis showed significantly more excessive daytime sleepiness and a worse quality 
of sleep in DRD compared to M-D patients (p=0.03 and p=0.02). 
In M-D, mean scores on the questionnaires concerning sleep and fatigue were not, or only 
marginally, above the clinical cut-off value (ESS=7.3, cut-off=10; PSQI= 5.9, cut-off=5; 
FSS=35, cut-off=36) and only the score indicating fatigue was significantly higher compared 
to controls (p=0.00).  
Quality of life  
The scores on the questionnaire concerning QoL differed between the four groups (see table 
3). Post hoc analysis showed a difference between M-D and CD patients (p=0.01), with a 
higher perceived physical QoL for the M-D patients (score of 50 vs. 44).  
Univariate analysis of the whole dystonia group showed a negative association between the 
QoL and almost all NMS (supplementary table 5). Multivariate analysis in the whole dystonia 
group showed that more fatigue (FSS) was associated with a lower physical QoL (β: -0.23, 
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p=0.00, supplementary table 6). More depressive and anxious symptoms were associated with 





To the best of our knowledge, this is the first study reporting on the prevalence of NMS in M-
D in direct comparison to other dystonia subtypes. We found a high prevalence of psychiatric 
disorders in all types of dystonia with more OCD and psychosis in M-D compared to CD and 
DRD patients. Further, dystonia patients had more sleep problems and fatigue than healthy 
controls. Compared to other dystonia subtypes, M-D patients reported less excessive daytime 
sleepiness and fatigue. QoL was lower in the dystonia groups compared to controls and 
associated with NMS, showing that NMS are an important burden for the dystonia patients.  
Psychiatric co-morbidity was highly prevalent in the M-D group with depressive disorder 
(36%), panic disorder (31%), agoraphobia (28%) and OCD (19%) being most common. 
Previous studies reported a comparable prevalence of these psychiatric disorders.[3,5] 
Conversely, compared to previous studies we found a low rate (7%) of alcohol dependence in 
our cohort.[4,5] We do not have a clear explanation for this finding, perhaps this is due to a 
greater awareness of the risks of alcohol dependence in M-D, or underreporting due to 
shameful feelings. 
Compared to DRD and CD patients, in M-D patients we saw a higher incidence of OCD and 
psychosis. Four M-D patients experienced some features of psychosis (including auditory 
and/or visual hallucinations and/or persecutory delusions ) at some point in their lives. This 
relatively high prevalence of psychosis in our cohort (10%)  has only been reported before in 
two M-D families.[24,25] Alterations of the dopaminergic signaling in the striatum are 
hypothesized to play a role in developing psychosis, especially an imbalance between D2 and 
D1 receptors have been reported and blockage of D2 receptors with antipsychotic treatment is 
in some cases successful.[26] In M-D the dopaminergic signaling in the striatum also plays a 
role, however, in a SGCE knock out mouse model and in M-D patients a reduced radiotracer 
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uptake of striatal D2 receptors was found.[27] Alterations in the dopaminergic system are part 
of the pathophysiology of both psychosis and M-D. This suggests that psychosis might be part 
of the phenotype of M-D, however the underlying mechanisms need further study.  
The relatively high prevalence of OCD in M-D is of special interest because OCD is not 
considered to be a consequence of living with a chronic disease. Although the precise 
pathophysiological pathways of both M-D and OCD are not fully known, some similarities 
have been suggested. Dysfunction of cortico-striatal connections is hypothesized to be 
responsible for OCD[28], and an altered long-term depression of the cortico-striatal synapses 
was found in a mouse model with a decreased expression of SGCE, representing M-D.[2] The 
globus pallidus interna (GPi) is another structure of interest and plays a role in both the 
pathophysiology of OCD and M-D. Successful deep brain stimulation (DBS) of the GPi in 
patients with Tourette syndrome and OCD has been described.[29] Similarly, GPi DBS has 
proven to be a successful treatment in MD and a previous study showed abnormal neuronal 
activity in the GPi of M-D patients compared to other dystonias.[30] Another clue that OCD 
and M-D share a common pathway is the role of mono-amine neurotransmitters, especially   
serotonin: in M-D, lower levels of serotonin metabolites in CSF have been reported.[31] In 
OCD, the serotonergic metabolism also plays a role, with selective serotonin reuptake 
inhibitors being the first and most effective pharmacological treatment option. The shared 
dysfunction in brain networks and the mono-amine neurotransmitters dopamine and serotonin  
are highly suggestive that NMS and motor symptoms in M-D have a common 
pathophysiological pathway. 
In our study we found an increased prevalence of anxiety disorders in all dystonia patients 
compared to controls. The prevalence of generalized anxiety (47%) in the DRD group was 
even higher than in M-D and CD patients. The serotonergic metabolism is also hypothesized 
to play a role in both DRD and generalized anxiety. The impaired synthesis of 
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tetrahydrobiopterin in DRD leads to an impaired synthesis of other mono amines such as 
serotonin.[32] In generalized anxiety, disruption of the serotonergic system, especially the 
pathway leading from the dorsal raphe nucleus via the amygdala to the frontal cortex, is 
known to play a role.[33] Although DRD was not the primary focus of our study, this further 
supports our hypothesis of a motor phenotype specific psychiatric phenotype with different, 
dystonia-syndrome-specific pathophysiological pathways at play.  
Apart from the psychiatric disorders, we found more fatigue in the M-D group compared to 
controls, however, fatigue scores in the M-D group were lower compared to the DRD 
patients. This might be due to the dopaminergic medication but could also be explained by 
changes of neurotransmitters in the basal ganglia, including serotonin and dopamine  which 
are suggested in fatigue.[34] Pathogenic variants in the SGCE gene (M-D) and GCH1 gene 
(DRD) might influence these neurotransmitter pathways in a different way, leading to 
dystonia-specific NMS. 
Our study has some limitations: first, the sample sizes of our groups were unequal. This 
unbalanced design was due to the rare nature of especially DRD. Furthermore, the age of 
onset of the dystonia subtypes was different in our cohort. Our analysis showed that age of 
onset influenced the odds ratio of OCD in M-D compared to CD patients. This might have 
had some influence on our finding of significantly more OCD in the M-D versus the CD 
patients. However, DRD patients have a similar age of onset as M-D patients but have a 
prevalence of OCD that is almost half the prevalence in M-D patients (11% vs. 20%). Another 
limitation of this study is the lack of antidepressant treatment in the CD group due to 
inclusion criteria of the previous study, which might have underestimated the rate of 
psychiatric disorders in this group. Eight CD patients were not included because they were 
using various antidepressants; and several additional patients were not asked to participate 
because of known medication use. The questionnaires about sleep disorders and fatigue were 
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not validated for use in dystonia patients. However, they are widely used and the ESS and 
FSS are shown to have good psychometric properties in dystonia patients.[35,36] In this 
study, some NMS, including  pain and cognitive problems, were not assessed. Further studies 
are recommended to characterize these symptoms in dystonia patients. 
In conclusion, dystonia patients have a high incidence of NMS, especially psychiatric 
features, sleep problems and fatigue, compared to controls. More specifically, in M-D patients 
the prevalence of OCD and psychosis is increased compared to CD and DRD patients, 
suggesting a disease specific motor and non-motor phenotype. This is further supported by the 
relatively increased incidence of generalized anxiety in DRD patients.  
Further research is necessary to elucidate the underlying pathways, with special attention for 
the involvement of neurotransmitters. Clinicians should be aware of the psychiatric co-
morbidity, sleep disturbances and fatigue in dystonia in general, with a special focus on OCD 
in M-D. The major influence of NMS on the QoL shows that NMS are an important burden 
for dystonia patients and highlights the necessity of early recognition and treatment of the 
NMS. An increased awareness for and personalized and adequate treatment of NMS might 
lead to an improved QoL of the patients.  
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